Literature DB >> 11796767

HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

A E Hensiek1, S J Sawcer, R Feakes, J Deans, A Mander, E Akesson, R Roxburgh, F Coraddu, S Smith, D A S Compston.   

Abstract

BACKGROUND: The association between multiple sclerosis and class II alleles of the major histocompatibility complex, in particular the DRB1*1501-DQB1*0602 haplotype, is well established but their role in determining specific features of this clinically heterogeneous disease is unknown as few studies involving large sample sizes have been performed.
METHODS: 729 patients with multiple sclerosis were typed for the HLA DR15 phenotype. All patients underwent clinical assessment and a detailed evaluation of their clinical records was undertaken.
RESULTS: The presence of DR15 was associated with younger age at diagnosis and female sex but there was no association with disease course (relapsing-remitting or secondary progressive v primary progressive type), disease outcome, specific clinical features (opticospinal v disseminated form), diagnostic certainty (clinically and laboratory supported definite v clinically probable multiple sclerosis), and paraclinical investigations including the presence of oligoclonal bands in the CSF or characteristic abnormalities on MRI imaging of the central nervous system.
CONCLUSION: Even though DR15 carriers are more likely to be female and prone to an earlier disease onset, the results indicate that there is no association with other specific clinical outcomes or laboratory indices examined here. This suggests that DR15 exerts a susceptibility rather than disease modifying effect in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796767      PMCID: PMC1737743          DOI: 10.1136/jnnp.72.2.184

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation.

Authors:  A E Harding; M G Sweeney; D H Miller; C J Mumford; H Kellar-Wood; D Menard; W I McDonald; D A Compston
Journal:  Brain       Date:  1992-08       Impact factor: 13.501

2.  Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.

Authors:  O Olerup; J Hillert; S Fredrikson; T Olsson; S Kam-Hansen; E Möller; B Carlsson; J Wallin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression.

Authors:  P Duquette; F Décary; J Pleines; D Boivin; G Lamoureux; J B Cosgrove; Y Lapierre
Journal:  Can J Neurol Sci       Date:  1985-05       Impact factor: 2.104

Review 4.  Genes and susceptibility to multiple sclerosis.

Authors:  D A Compston; H Kellar Wood; N Robertson; S Sawcer; N W Wood
Journal:  Acta Neurol Scand Suppl       Date:  1995

5.  HLA and prognosis in multiple sclerosis.

Authors:  B Runmarker; T Martinsson; J Wahlström; O Andersen
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

6.  HLA and heterogeneity of multiple sclerosis.

Authors:  T Engell; N E Raun; M Thomsen; P Platz
Journal:  Neurology       Date:  1982-09       Impact factor: 9.910

7.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

8.  An immunogenetic heterogeneity in multiple sclerosis.

Authors:  J Hillert; M Grönning; H Nyland; H Link; O Olerup
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

10.  Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells.

Authors:  F Zipp; F Weber; S Huber; S Sotgiu; A Czlonkowska; E Holler; E Albert; E H Weiss; H Wekerle; R Hohlfeld
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

View more
  32 in total

Review 1.  Genetic analysis of multiple sclerosis.

Authors:  Alastair Compston; Stephen Sawcer
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 2.  Multiple sclerosis, vitamin D, and HLA-DRB1*15.

Authors:  Lahiru Handunnetthi; Sreeram V Ramagopalan; George C Ebers
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

Review 3.  New approaches to investigating heterogeneity in complex traits.

Authors:  R Bomprezzi; P E Kovanen; R Martin
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

Review 4.  The genetics of multiple sclerosis: an up-to-date review.

Authors:  Pierre-Antoine Gourraud; Hanne F Harbo; Stephen L Hauser; Sergio E Baranzini
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 5.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

6.  Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Authors:  An Goris; Ine Pauwels; Marte W Gustavsen; Brechtje van Son; Kelly Hilven; Steffan D Bos; Elisabeth Gulowsen Celius; Pål Berg-Hansen; Jan Aarseth; Kjell-Morten Myhr; Sandra D'Alfonso; Nadia Barizzone; Maurizio A Leone; Filippo Martinelli Boneschi; Melissa Sorosina; Giuseppe Liberatore; Ingrid Kockum; Tomas Olsson; Jan Hillert; Lars Alfredsson; Sahl Khalid Bedri; Bernhard Hemmer; Dorothea Buck; Achim Berthele; Benjamin Knier; Viola Biberacher; Vincent van Pesch; Christian Sindic; Annette Bang Oturai; Helle Bach Søndergaard; Finn Sellebjerg; Poul Erik H Jensen; Manuel Comabella; Xavier Montalban; Jennifer Pérez-Boza; Sunny Malhotra; Jeannette Lechner-Scott; Simon Broadley; Mark Slee; Bruce Taylor; Allan G Kermode; Pierre-Antoine Gourraud; Stephen J Sawcer; Bettina Kullle Andreassen; Bénédicte Dubois; Hanne F Harbo
Journal:  Brain       Date:  2015-01-22       Impact factor: 13.501

Review 7.  The intelligent use and clinical benefits of electronic medical records in multiple sclerosis.

Authors:  Mary F Davis; Jonathan L Haines
Journal:  Expert Rev Clin Immunol       Date:  2014-12-11       Impact factor: 4.473

8.  HLA complex-linked heat shock protein genes and childhood acute lymphoblastic leukemia susceptibility.

Authors:  Esma Ucisik-Akkaya; Charronne F Davis; Clara Gorodezky; Carmen Alaez; M Tevfik Dorak
Journal:  Cell Stress Chaperones       Date:  2009-12-09       Impact factor: 3.667

9.  Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.

Authors:  Cathy J Jensen; Jim Stankovich; Anneke Van der Walt; Melanie Bahlo; Bruce V Taylor; Ingrid A F van der Mei; Simon J Foote; Trevor J Kilpatrick; Laura J Johnson; Ella Wilkins; Judith Field; Patrick Danoy; Matthew A Brown; Justin P Rubio; Helmut Butzkueven
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

10.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.